Trials / Completed
CompletedNCT03018509
Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JTE-451 Administered for 4 Weeks in Subjects With Active Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Akros Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effect of JTE-451 administered for 4 weeks in subjects with active plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JTE-451 | Active drug tablets containing JTE-451 |
| DRUG | Placebo | Placebo tablets identical in appearance to the active drug tablets |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-06-20
- Completion
- 2017-06-20
- First posted
- 2017-01-12
- Last updated
- 2017-07-02
Locations
5 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03018509. Inclusion in this directory is not an endorsement.